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The Editorial on the Research Topic
Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality
Immunogenic cell death (ICD) has emerged as a cornerstone of therapy-induced antitumor immu-
nity (1–3). ICD is distinguished by spatiotemporally defined emission of danger signals or damage-
associated molecular patterns (DAMPs) that elevate the immunogenic potential of dying cells [Garg 
et al.; (4)]. The important role played by DAMPs in immunity, tissue remodeling, and inflammation 
is discussed in details by Venereau et al. (Marco E. Bianchi lab).
Most potent ICD inducers, characterized so far, elicit danger signaling through oxidative-
endoplasmic reticulum stress (5). Several ICD inducers have been characterized, e.g., some chemo-
therapies, some physicochemical therapies (e.g., radiotherapy or photodynamic therapy/PDT), and 
oncolytic viruses (2, 6). Here, radiotherapy is among the first recognized immunogenic therapies 
[on account of “abscopal-effect” (7)]. The immunogenic potential of radiotherapy and possibilities 
for its combination with immune checkpoint blockers is discussed by Derer et al. (Udo S. Gaipl 
lab). It is noteworthy that ICD can also be achieved by various “smart” combinatorial strategies – an 
important point for clinically applied non-ICD inducers, discussed in details by Bezu et al. (Guido 
Kroemer lab).
Several lines of experimental evidence have established the validity of ICD. However, the overreli-
ance on usage of prophylactic vaccination in transplantable (heterotopic) tumor models has attracted 
some criticism (8). While these criticisms are valid, the field is already moving toward tumors pro-
duced orthotopically (curative/therapeutic) or in genetically engineered mouse models (GEMM) (at 
least for few ICD inducers, e.g., hypericin-PDT, Newcastle disease virotherapy and anthracyclines) 
(9–12). Moreover, the clinical existence of ICD has been proven through retrospective analysis 
involving cancer patient’s survival/therapy-responsiveness data (13–17). These observations have 
encouraged the increased usage of ICD-associated DAMPs as predictive/prognostic biomarkers – a 
point discussed in detail by Fucikova et al. (Radek Spisek lab). The promising results generated by 
systemically administered ICD inducers have also paved way for application of ICD-based dendritic 
cell (DC) vaccines (12). This important development has been discussed from the preclinical/clinical 
vantage points of various solid tumors by Vandenberk et al. (Stefaan W. van Gool lab) and lymphoma 
by Zappasodi et al. (Massimo Di Nicola lab). In the latter case, it is clear that the field is moving 
toward chimeric antigen receptor (CAR)-T cell’s application, and it will be interesting to see its 
combination with ICD in near future.
Nevertheless, the insurmountable complexity of cancer makes it inevitable that in certain 
contexts, ICD may fail. This failure may stem from various factors, e.g., tumor heterogeneity (8), 
MHC-level heterogeneity (12), pre-established niches enriched in immunosuppressive factors or 
immune-checkpoints (1), stem cell-based immune-evasion (12), low mutational load, inactivating 
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mutations/polymorphisms in certain immune-receptors (1), 
general ablation of danger signaling (14), and other genetic or 
even epigenetic causes. Several of these pro-cancerous immune-
evasive mechanisms and immunotherapeutic strategies required 
for overcoming them are discussed in detail by Kersten et  al. 
(Karin E. de Visser lab). The strategies for targeting epigenetic 
processes to improve immunotherapy are further discussed by 
Wachowska et al. (Jakub Golab lab).
We believe that the valuable contributions of key researchers/
clinicians toward this research topic/special edition have largely 
fulfilled its primary aim, i.e., to foster a critical discussion on 
experimental and clinical relevance of ICD. In fact, to further sum-
marize and organize the fields of ICD and DAMPs, we have pro-
duced a multi-author consensus paper within this research topic 
that attempts to classify DAMPs and ICD inducers with an eye on 
translational potential of ICD (Garg et al.). This classification paper 
brings together >50 authors from the fields of ICD and DAMPs, 
and tries to reach a comprehensive accord on various terminolo-
gies related to DAMPs/ICD, the historical background of these 
concepts, ICD classification system (Type I vs. Type II inducers), 
and the relevant preclinical/clinical criteria crucial for the field(s) 
(Garg et al.). We hope that this consensus paper will be a use-
ful literature resource for various researchers/clinicians. These 
contributions, while summarizing the status quo, have also 
exposed a set of major questions and challenges that still need 
to be addressed.
MaJor QUEStioNS to rESolVE
  1. Which danger signaling module is most specific to ICD? 
Ecto-CRT seems to have remarkable exclusivity to ICD (10, 
18–20) yet certain ICD inducers do not induce secreted-ATP 
(10), released-HMGB1 (19), or Type I IFN-responses (21). 
Alternatively, many non-ICD inducers induce secreted-ATP 
(22), released-HMGB1 (23), or Type I IFN-response (21). In 
fact, Type I IFN-responses can neutralize oncolytic viruses 
through antiviral signaling (24).
  2. Are ICD-associated DAMPs interchangeable? Ecto-HSP90 
was proposed to be interchangeable with ecto-CRT (25, 26), 
but this was recently invalidated in another set-up (21).
  3. Could ICD-associated DAMPs act as bystanders in certain 
contexts? Induction of ICD-associated DAMPs may not 
always translate into a relevant functional outcome, e.g., 
Bleomycin induces all ICD-associated DAMPs yet elicits 
Tregs induction (27).
  4. What is the full extent of “plasticity” of ICD-associated danger/
immunogenic signaling?
  5. What is the exact role of cellular catabolic processes in 
regulating ICD? Current results are highly variable; while 
macroautophagy positively regulates secreted-ATP (28), yet 
it can also negatively regulate ecto-CRT (29–31). Also, the 
exact roles of chaperone-mediated autophagy/CMA [CMA-
essential gene Lamp2a regulates ecto-CRT (29)] or protea-
some activity remains unresolved (Bortezomib induces ICD 
but not MG132, yet both inhibit the proteasome) (5).
  6. What are the common molecular determinants of ICD across 
various cell death pathways? ICD-profile is largely associated 
with caspase-dependent apoptosis (18) but association with 
necroptosis is also emerging (10).
  7. How does ICD counter-act the (innately) apoptosis-associated 
immunosuppressive processes?
  8. Does the role of ROS in ICD extend beyond a proximal 
stressor? e.g., ROS-elicited oxidation-associated molecular 
patterns/OAMPs have been shown to mediate immunogenic 
potential (11).
  9. Why ICD fails in certain (GEMM) cancer mice models (8) but 
works in others (9, 32)?
 10. Can epigenetic events [e.g., Long non-coding/micro-RNA 
(33)] regulate ICD and how?
traNSlatioNal/CliNiCal 
CHallENGES
 1. Can ICD’s clinical translation withstand the “adverse effects” of 
mice-to-human immune differences?
 2. Confirming ICD’s existence in a prospective (high-powered/
supervised) clinical trial.
 3. Can ICD withstand the (clinical-)operational/regulatory (GLP/
GMP/GCP) hurdles associated with anticancer vaccines-
production? [indications for which are emerging (12)]
 4. Characterizing ICD-resistance mechanisms in the clinic.
 5. Characterizing reliable ICD-biomarker(s) detectable in patient 
tumor/sera-samples.
 6. Investigating ICD as a source of robust prognostic/predictive/
mechanistic biomarkers [a point investigated recently in some 
studies (13, 34)].
We believe that the operational function of ICD (i.e., a 
dying cancer cell eliciting heightened immunogenicity-driven 
antitumor immunity) is incontrovertibly valid; but, owing to the 
incomprehensible complexity of cancer, the “specifics of ICD” 
(i.e., its molecular, signaling, and immunological determinants) 
will always remain open to amenability and variations. We envis-
age that overtime various “variants” of ICD may emerge that 
differ from each other in a manner dependent upon, the type 
of anticancer therapy, cancer cell death pathways, cancer-types, 
tumor antigen make-up, the in  vivo/in  situ location, and the 
location-dependent immune-contexture.
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